Press coverage about Bruker (NASDAQ:BRKR) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bruker earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.0975377541879 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Bruker stock traded up $0.20 during trading on Tuesday, hitting $29.13. The company’s stock had a trading volume of 10,858 shares, compared to its average volume of 586,093. The firm has a market capitalization of $4.53 billion, a P/E ratio of 24.03, a PEG ratio of 1.85 and a beta of 1.17. Bruker has a 1-year low of $26.98 and a 1-year high of $36.53. The company has a current ratio of 2.22, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, May 3rd. The medical research company reported $0.24 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.02. The firm had revenue of $431.70 million during the quarter, compared to analyst estimates of $419.25 million. Bruker had a return on equity of 27.04% and a net margin of 4.63%. The business’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.19 earnings per share. equities analysts predict that Bruker will post 1.39 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, June 22nd. Shareholders of record on Monday, June 4th were paid a dividend of $0.04 per share. The ex-dividend date was Friday, June 1st. This represents a $0.16 annualized dividend and a yield of 0.55%. Bruker’s dividend payout ratio is presently 13.22%.

Several analysts have recently issued reports on the company. BTIG Research set a $42.00 price objective on Bruker and gave the company a “buy” rating in a research report on Sunday, May 6th. BidaskClub upgraded Bruker from a “hold” rating to a “buy” rating in a research report on Wednesday, May 23rd. Zacks Investment Research downgraded Bruker from a “buy” rating to a “hold” rating in a research report on Friday, June 8th. Bank of America reduced their price objective on Bruker from $37.00 to $34.00 and set a “neutral” rating on the stock in a research report on Friday, May 4th. Finally, Morgan Stanley dropped their target price on Bruker from $32.00 to $31.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 11th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $32.91.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Insider Buying and Selling by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with's FREE daily email newsletter.